HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LIVN
LivaNova PLC
LIVN's fundamentals are mixed: it returned to profit, but its operating margin fell 4 points to 11%. At 30x earnings, it's trading less than half its usual 113x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LIVN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
LIVN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LIVN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $90.20 | — |
| Cheap | 29x | $87.18 | -3.3% |
| Current | 30x | $90.20 | — |
| Fair | 112x | $337 | +274% |
| Expensive | 769x | $2,314 | +2465% |
Historical ranges are pointers, not guarantees.
LIVN's PE is in its cheap range at 30x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LIVN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
LIVN has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LIVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.53 | +50% |
| Q3 2026 | $3.01 | +$6.99 |
| Q2 2026 | $3.39 | +$7.26 |
| Q1 2026 | $1.96 | +$6.03 |
| Q4 2025 | -$4.45 | -484% |
| Q3 2025 | -$3.98 | -1048% |
| Q2 2025 | -$3.87 | -$3.55 |
| Q1 2025 | -$4.07 | -$3.47 |
| Q4 2024 | $1.16 | +262% |
LIVN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LIVN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
LIVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $393.1M | +9.9% |
| Q2 2026 | $390.6M | +11% |
| Q1 2026 | $362.3M | +14% |
| Q4 2025 | $360.9M | +12% |
| Q3 2025 | $357.8M | +12% |
| Q2 2025 | $352.5M | +11% |
| Q1 2025 | $316.9M | +7.4% |
| Q4 2024 | $321.8M | +3.8% |
LIVN's revenue has grown year over year for 16 quarters in a row: $393M last quarter, up 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | -7.9 points |
| Q2 2026 | 13% | -2.7 points |
| Q1 2026 | 11% | -3.9 points |
| Q4 2025 | 12% | +0.3 points |
| Q3 2025 | 15% | +3.9 points |
| Q2 2025 | 15% | +2.8 points |
| Q1 2025 | 15% | +9.8 points |
| Q4 2024 | 12% | +40 points |
LIVN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over LIVN on cash flow, with more consistent year-over-year improvement.
LIVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $42.9M | -31% |
| Q2 2026 | $35M | -27% |
| Q1 2026 | $926K | -93% |
| Q4 2025 | $50.2M | -27% |
| Q3 2025 | $62.2M | +89% |
| Q2 2025 | $47.8M | +53% |
| Q1 2025 | $13.2M | +268% |
| Q4 2024 | $68.3M | +66% |
LIVN still generates free cash flow, though less than at its 2024 peak: $129M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LIVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LIVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +1.1M shares |
| 1 year | +4% | +2.2M shares |
| 3 years | +6.3% | +3.4M shares |
| 5 years | +11% | +5.8M shares |
| Available history | +19% | +9M shares |
LIVN has 57M diluted shares, up 4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LIVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.6x | Net Cash |
| Q4 2024 | 1.3x | Healthy |
LIVN has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LIVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.0 | Neutral |
| Stochastic | 56.1 | Neutral |
LIVN's weekly RSI is 67 (neutral) and its Stochastic is 56 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LIVN PE vs Healthcare Sector
| Metric | LIVN | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 16% above |
| PE % | 19 | 29 | 10 pts below |
LIVN is trading at 30x earnings, a 16% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LIVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 12% above |
| 20 week MA | $80.3 | 12% above |
| 50 week MA | $72.3 | 25% above |
| 100 week MA | $59.7 | 51% above |
| 200 week MA | $55.5 | 62% above |
LIVN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
LIVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $75.4 | $67.4 | -11% |
| 2021 | $67.4 | $85.2 | +26% |
| 2022 | $85.2 | $53.7 | -37% |
| 2023 | $53.7 | $51.7 | -3.6% |
| 2024 | $51.7 | $46.6 | -10% |
| 2025 | $46.6 | $62.9 | +35% |
| 2026 YTD | $62.9 | $90.2 | +43% |
LIVN has the edge over HIMS on returns for 2026, with the stronger performance.